Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Enfortumab vedotin (EV) monotherapy shows effectiveness in advanced urothelial carcinoma (UC). Prior avelumab maintenance therapy, compared to pembrolizumab, resulted in significantly better overall survival outcomes for patients receiving EV.
Area Of Science
- Oncology
- Urothelial Carcinoma Research
- Pharmacotherapy
Background
- Advanced urothelial carcinoma (UC) presents challenges for late-line treatment.
- Evaluating enfortumab vedotin (EV) efficacy based on prior immune checkpoint inhibitor (ICI) therapy is crucial.
Purpose Of The Study
- To assess the effectiveness of enfortumab vedotin (EV) monotherapy as a late-line treatment for advanced urothelial carcinoma (UC).
- To compare EV outcomes in patients pretreated with avelumab maintenance versus pembrolizumab therapy.
Main Methods
- Retrospective analysis of 80 advanced UC patients treated with EV after failure of platinum-based chemotherapy and ICI therapy.
- Comparison of objective response rate, progression-free survival (PFS), and overall survival (OS) between patients who received avelumab or pembrolizumab before EV.
Main Results
- Both avelumab and pembrolizumab groups showed comparable objective response and disease control rates.
- No significant difference in PFS was observed between the groups.
- The avelumab group demonstrated significantly better overall survival (OS) from EV initiation (16.0 vs. 10.2 months, p=0.019).
- Avelumab maintenance therapy before EV was associated with a reduced mortality risk (47%).
Conclusions
- Enfortumab vedotin (EV) monotherapy is an effective late-line treatment for advanced urothelial carcinoma (UC).
- Prior avelumab maintenance therapy, compared to pembrolizumab, is associated with improved survival outcomes in patients receiving EV.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...